ADMA Biologics Inc logo

ADMA Biologics Inc

NEW
NAS:ADMA (USA)   Ordinary Shares
$ 9.38 +0.26 (+2.79%) 01:40 PM EST
13.31
P/B:
5.19
Market Cap:
$ 2.10B
Enterprise V:
$ 2.16B
Volume:
961.26K
Avg Vol (2M):
2.31M
Trade In:
Volume:
961.26K
Avg Vol (2M):
2.31M

ADMA Number of Guru Trades

To

ADMA Volume of Guru Trades

To

ADMA Daily Net ETF Flow

Dollars ETFs put into or pulled out of ADMA each day, net of sells, against the share price.

ADMA Daily Net ETF Share Flow

Shares ETFs added or removed each day, net, as a share of ADMA's shares outstanding, against the share price.

Gurus Latest Trades with NAS:ADMA

No Available Data

NAS:ADMA is held by these investors

Guru
Portfolio Date
Current Shares
% of Shares outstanding
% of Total Assets Managed
Comment
Joel Greenblatt
2026-06-30
73,829
0.030
0%
New holding
Total 1

Top ETF Buyers

What each ETF bought and sold in this stock over the period, from the same daily data as the charts above. Sorted by net amount, so sorting ascending brings the heaviest sellers to the top.

ETF
ETF Name
Net Amount $Mil
Buy Amount $Mil
Sell Amount $Mil
Net Share Change
# of Days Traded
Current Shares
20/Page
Total 0

ETF Ownership

Every ETF holding the stock, largest position first. Change covers the gap between each fund's last two reports, so a fund that held still shows none.

ETF
ETF Name
Shares
% of Shares Out
Change (Last Report)
Action
Report Date
Price Range
20/Page
Total 0

Guru Commentaries on NAS:ADMA

2025 Q2
What the manager wrote

During the quarter we added several new ideas, including Insmed, ADMA Biologics, HealthEquity, Waystar, and Alignment Healthcare. Biotech continues to be a significant weight in the R2500G, and we continue to believe commercial stage companies with marketed products have strong growth prospects. ADMA has unique manufacturing capabilities for plasma-derived therapeutics and should continue to gain market share and drive profitable growth for the next several years.

2025 Q1
small cap quality growth q1 commentary
What the manager wrote

ADMA Biologics (ADMA) had another outstanding quarter and guided metrics higher. This performance is indicative of the company's strong position within the health care sector, particularly in biotechnology. The positive guidance suggests that ADMA is well-positioned for future growth, aligning with our strategy of investing in high-quality growth companies. The overall performance of our portfolio, which includes ADMA, reflects our focus on companies that exhibit stable, consistent growth and attractive valuations.

News about NAS:ADMA

Total 0
  • 1